Evidence map›Paper›PMID 31320815›Full record

ArticleTurkish journal of biology = Turk biyoloji dergisi2019

Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease).

Sevil Köse, Fatima Aerts Kaya, Barış Kuşkonmaz, Duygu Uçkan Çetinkaya

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of biology = Turk biyoloji dergisi, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sevil KöseDepartment of Medical Biology and Genetics, Faculty of Medicine, Atılım University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-2188-9534
Fatima Aerts KayaCenter for Stem Cell Research and Development (PEDI-STEM), Hacettepe University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-9583-8572
Barış KuşkonmazCenter for Stem Cell Research and Development (PEDI-STEM), Hacettepe University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-1207-4205
Duygu Uçkan ÇetinkayaCenter for Stem Cell Research and Development (PEDI-STEM), Hacettepe University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-3593-6493
Hacettepe University Hospital · TRAnkara University · TRHacettepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucolipidosis type II (ML-II, I-cell disease) is a fatal inherited lysosomal storage disease caused by a deficiency of the enzyme N-acetylglucosamine-1-phosphotransferase. A characteristic skeletal phenotype is one of the many clinical manifestations of ML-II. Since the mechanisms underlying these skeletal defects in ML-II are not completely understood, we hypothesized that a defect in osteogenic differentiation of ML-II bone marrow mesenchymal stem cells (BM-MSCs) might be responsible for this skeletal phenotype. Here, we assessed and characterized the cellular phenotype of BM-MSCs from a ML-II patient before (BBMT) and after BM transplantation (ABMT), and we compared the results with BM-MSCs from a carrier and a healthy donor. Morphologically, we did not observe differences in ML-II BBMT and ABMT or carrier MSCs in terms of size or granularity. Osteogenic differentiation was not markedly affected by disease or carrier status. Adipogenic differentiation was increased in BBMT ML-II MSCs, but chondrogenic differentiation was decreased in both BBMT and ABMT ML-II MSCs. Immunophenotypically no significant differences were observed between the samples. Interestingly, the proliferative capacity of BBMT and ABMT ML-II MSCs was increased in comparison to MSCs from age-matched healthy donors. These data suggest that MSCs are not likely to cause the skeletal phenotype observed in ML-II, but they may contribute to the pathogenesis of ML-II as a result of lysosomal storage-induced pathology.

Indexed as

bone marrowI-cell diseaselysosomal storage diseasemesenchymal stem cellsMucolipidosis type II

Identifiers

PMID31320815
PMCPMC6620033
OpenAlexW2953370444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.